Literature DB >> 2953811

Urokinase: a chemotactic factor for polymorphonuclear leukocytes in vivo.

M D Boyle, V A Chiodo, M J Lawman, A P Gee, M Young.   

Abstract

The effects of injecting urokinase into subdermal air sacs on the back of mice was studied. Urokinase was leukotactic in the concentration range of 2 X 10(-13) to 2 X 10(-15) M. This response was absolutely dependent on the enzyme activity of the serine esterase, but was found to be independent of generation of the chemotactic complement split product C5a. At high doses of urokinase (greater than 2 X 10(-12) M), no cellular infiltration was observed. Injection of 2 X 10(-10) M urokinase i.p. led to the systemic desensitization of mice when challenged in the skin with a lower dose (2 X 10(-14) M) of urokinase. Urokinase desensitization did not alter the ability of mice to respond to the chemical chemotactic factor f-met-leu-phe or to respond to C5a-dependent chemotactic stimuli. Urokinase desensitized mice failed to demonstrate a chemotactic response to nerve growth factor, thrombin, plasmin, or factor X activating enzyme, all of which were chemotactic in non-urokinase pre-treated animals. The results of these studies indicate the presence of three physiologically independent inflammatory pathways in mice: independent of C5 and not influenced by pretreatment with urokinase, independent of C5 and inhibited by pretreatment with urokinase, and dependent on C5 and not influenced by pretreatment with urokinase.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2953811

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues.

Authors:  Z Szekanecz; G K Haines; A E Koch
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

2.  Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.

Authors:  Bénédicte Chazaud; Rémy Ricoux; Christo Christov; Anne Plonquet; Romain K Gherardi; Georgia Barlovatz-Meimon
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

3.  Improvement of wound tissue repair by chitosan films containing (-)-borneol, a bicyclic monoterpene alcohol, in rats.

Authors:  Rosana Ss Barreto; Jullyana Ss Quintans; André S Barreto; Ricardo Lc Albuquerque-Júnior; Juliana G Galvão; Joice Kmc Gonsalves; Rogéria S Nunes; Enilton A Camargo; Waldecy Lucca-Júnior; Rosilene C Soares; Vera Lúcia C Feitosa; Lucindo J Quintans-Júnior
Journal:  Int Wound J       Date:  2014-12-04       Impact factor: 3.315

4.  Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement.

Authors:  Andrew D Cook; Christine M De Nardo; Emma L Braine; Amanda L Turner; Ross Vlahos; Kerrie J Way; S Kaye Beckman; Jason C Lenzo; John A Hamilton
Journal:  Arthritis Res Ther       Date:  2010-03-02       Impact factor: 5.156

5.  The urokinase receptor is required for human monocyte chemotaxis in vitro.

Authors:  M R Gyetko; R F Todd; C C Wilkinson; R G Sitrin
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

6.  Association between expression of immunoglobulin G-binding proteins by group A streptococci and virulence in a mouse skin infection model.

Authors:  R Raeder; M D Boyle
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

7.  Role of alveolar macrophages in lipopolysaccharide-induced neutrophil accumulation.

Authors:  A G Harmsen
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

8.  Inactivation of human tumor cell pro-urokinase by granulocyte elastase.

Authors:  N Kanayama; T Terao
Journal:  Jpn J Cancer Res       Date:  1990-10

9.  Distinct cellular functions mediated by haemopoietic cell-surface proteases.

Authors:  B Bauvois; A Laouar
Journal:  Adv Neuroimmunol       Date:  2007-03-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.